Carcinoid tumors: Molecular genetics, tumor biology, and update of diagnosis and treatment

Current Opinion in Oncology

Volumn 14, Issue 1, 2002, Pages 38-45

  Öberg, Kjell ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; ANGIOPEPTIN; CHROMOGRANIN A; EPIDERMAL GROWTH FACTOR RECEPTOR; GENE PRODUCT; IODINE 131; OCTREOTIDE; PROTEIN MEN1; SOMATOSTATIN DERIVATIVE; THYROID TRANSCRIPTION FACTOR 1; TRANSFORMING GROWTH FACTOR ALPHA; UNCLASSIFIED DRUG; YTTRIUM 90;

CANCER CELL; CANCER RADIOTHERAPY; CANCER SURGERY; CARCINOGENESIS; CARCINOID; CELL PROLIFERATION; CHROMOSOME 18; CLINICAL TRIAL; CYTOSTASIS; DIAGNOSTIC IMAGING; GENE DELETION; HUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SCINTIGRAPHY; SYMPTOM; TUMOR LOCALIZATION;

CARCINOID TUMOR; CHROMOGRANINS; HUMANS; MOLECULAR BIOLOGY; TUMOR MARKERS, BIOLOGICAL;

EID: 0036145014     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-200201000-00008     Document Type: Review

References (59)

1. Pathobiology and classification of gut endocrine tumors
2. Carcinoid and pancreatoid endocrine tumors: Recent advances in molecular pathogenesis, localization, and treatment
3. Natural history of digestive endocrine tumors
4. Carcinoid tumors
5. Carcinoid tumors: Current concepts in diagnosis and treatment
6. New insights in genetics of digestive neuroendocrine tumors
7. Identification of MEN-1 gene mutations in sporadic carcinoid tumors of the lung
8. Typical and atypical carcinoid tumors of the lung are characterized by 11q deletions as detected by comparative genomic hybridization
9. Loss of heterozygosity in 11q13-14 regions in gastric neuroendocrine tumors not associated with multiple endocrine neoplasia type 1 syndrome
10. Mutations and allelic deletions of the MEN-1 gene are associated with a subset of sporadic endocrine pancreatic and neuroendocrine tumors and not restricted to foregut neoplasms
11. Genetic changes in the spectrum of neuroendocrine lung tumors
12. In frequent mutations of the p53 gene in pulmonary carcinoid tumors
13. Identification of p53 gene mutations in gastrointestinal and pancreatic carcinoids by nonradioisotopic SSCA
14. Genomic alteration in well-differentiated gastrointestinal and bronchial neuroendocrine tumors (carcinoids)
15. Comparative genomic hybridization identifies loss of 18q22-qter as an early and specific event in tumorigenesis of midgut carcinoids
16. Loss of heterozygosity on chromosome arm 11q in lung carcinoids
17. Growth characteristics of rectal carcinoid tumors
18. Goblet cell carcinoid of the appendix
19. Goblet cell carcinoid of the appendix
20. A retrospective analysis of 1570 appendiceal carcinoids
21. Goblet cell carcinoids of the appendix
22. Neuroendocrine carcinomas (carcinoid tumor) of the thymus
23. Pulmonary atypical carcinoid: Predictors of survival in 106 cases
24. Typical and atypical pulmonary carcinoids: Outcome in patients presenting with regional lymph node involvement
25. The Niigata registry for gut-pancreatic endocrinomas
26. Carcinoid tumors: A statistical analysis of a Japanese series of 3,126 reported and 1,180 autopsy cases
27. Carcinoids of the ovary: An analysis of 329 reported cases
28. Thyroid transcription factor-1 distinguishes metastatic pulmonary from well-differentiated neuroendocrine tumors of other sites
29. Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatinin plasma and urine from patients with carcinoid tumors and endocrine pancreatic tumors
30. Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors
31. Diagnostic value of plasma chromogranin A in neuroendocrine tumors
32. Insulin-like growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells
33. Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors
34. Value of somatostatin receptor scintigraphy: A prospective study in gastrinoma of its effect on clinical management
35. Comparison of somatostatin analog and meta-iodo-benzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors
36. 1]-octreotide imaging
37. Ability of somatostatin receptor scintigraphy to identify patients with gastric carcinoids: A prospective study
38. Positron emission tomography with 5-hydroxy-tryptophan in neuroendocrine tumors
39. 64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors
40. Progression of metastases and symptom improvement from laparotomy in midgut carcinoid tumors
41. Survival and daily physica activity in patients treated for advanced midgut carcinoid tumors
42. Surgical treatment as a principle in patients with advanced abdominal carcinoid tumors
43. Gastrointestinal carcinoid tumors: Long-term prognosis for surgically treated patients
44. Method for dissection of mesenteric metastases in midgut carcinoid tumors
45. Surgery as primary treatment in patients with liver metastases from carcinoid tumors: A retrospective, unicentric study over 13 years
46. Digestive endocrine tumor management: Medical advanced disease
47. A phase II study of high-dose paclitaxel in patients with advanced neuroendocrine tumors
48. The use of new somatostatin analogues, lanreotide and octastatin, in neuroendocrine gastro-intestinal tumors
49. High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: Clinical and biologic effects
50. Somatostatin analogue octreotide and inhibition of tumor growth in metastatic endocrine gastroenteropancreatic tumors
51. Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors
52. Antitumor activity of somatostatin analogues in progressive metastatic neuroendocrine tumors
53. Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide
54. Palliative effect of metaiodobenzyl-guanidine in metastatic carcinoid tumors
55. 131I-MIGB treatment by predosing with non-radiolabeled MIGB in carcinoid patients, and studies in xenografted mice
56. Radiolabeled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy
57. 1]-octreotide in patients with neuroendocrine tumors
58. Response to treatment with yt-trium 90-DOTA-lanreotide of a patient with metastatic gastrinoma
59. 90Y-DOTATOC) in the treatment of neuroendocrine tumors: A clinical phase II study